Welcome to our dedicated page for Rafael Holdings news (Ticker: RFL), a resource for investors and traders seeking the latest updates and insights on Rafael Holdings stock.
Rafael Holdings (RFL) is a diversified holding company focused on clinical stage therapeutics, infusion technology, and strategic real estate. This page serves as your centralized source for official news, press releases, and updates across all business segments.
Access timely announcements on RFL's clinical development programs, mergers, and portfolio expansions. Investors will find critical updates on healthcare investments, infusion technology advancements, and real estate acquisitions. Content includes earnings reports, partnership agreements, and regulatory milestones.
Bookmark this page for direct access to RFL's verified corporate communications. Check regularly for insights into the company's progress in addressing high unmet medical needs and its balanced investment strategy across high-growth and stable sectors.
Rafael Holdings, Inc. (NYSE: RFL) reported its financial results for the three and nine months ended April 30, 2022. The company had cash reserves of $59.4 million and incurred a net loss of $5.5 million for Q3, up from $2.6 million the previous year. Revenue for the quarter was $0.9 million, slightly down from $1 million. Over the first nine months, net loss totaled $119.9 million, significantly higher than $12.2 million in the prior year, primarily due to an impairment loss. R&D expenses increased to $6.9 million as the company focuses on its early-stage drug development pipeline.
Cranbury, NJ, June 1, 2022 - Cornerstone Pharmaceuticals, formerly Rafael Pharmaceuticals, announced three abstracts will be presented at the ASCO Annual Meeting from June 3-7, 2022, in Chicago. These abstracts focus on CPI-613® (devimistat) in treating rare cancers, specifically clear cell sarcoma and biliary tract cancer, with special emphasis on pancreatic cancer. Key presentations will be made by notable researchers, discussing promising trial results. The company aims to advance treatment options for patients suffering from rare cancers.
Cranbury, NJ (May 24, 2022) – Cornerstone Pharmaceuticals announced that the European Medicines Agency (EMA) has granted orphan drug designation to CPI-613® (devimistat) for treating advanced unresectable biliary tract cancer. This rare cancer affects over 2,000 people annually in the UK, with increasing incidence rates. The designation marks the fourth for devimistat by the EMA, which is also recognized by the FDA for seven indications in the U.S. Strong Phase 2 trial enrollment suggests promise for devimistat in addressing significant unmet clinical needs in biliary tract cancer.
Cranbury, NJ, May 19, 2022 – Rafael Pharmaceuticals has officially changed its name to Cornerstone Pharmaceuticals, aligning with its mission to develop therapies for rare cancers. The company emphasized its commitment to addressing significant unmet needs in cancer treatment through its lead compound, CPI-613® (devimistat), which has received orphan drug designation from the FDA for multiple cancers.
Ongoing clinical trials for Burkitt's lymphoma, biliary tract cancer, and clear cell sarcoma are meeting key milestones, with new trials expected to launch in Q2 and Q3 2022.
Rafael Holdings, Inc. (NYSE: RFL) reported its financial results for the second quarter of fiscal 2022, ending January 31, 2022. The company experienced a net loss of $2.3 million, or $0.12 per share, significantly reduced from a $8.2 million loss in the same quarter of the previous year. Revenues slightly increased to $1.1 million. R&D expenses surged to $3.3 million, reflecting advancements in their pipeline. The company holds $65.0 million in cash and cash equivalents, with a total net loss of $114.3 million for the first half fiscal 2022.
Rafael Holdings, Inc. (NYSE: RFL) announced leadership changes, with Bill Conkling taking over as CEO from Ameet Mallik on February 1, 2022. Conkling has over 20 years of experience in oncology, previously holding key leadership roles at Immunomedics and Novartis Oncology. Dr. Rick Ewing is appointed as Head of Drug Discovery, bringing over 30 years of experience from Bristol Myers Squibb. Mallik will remain on the Board of Directors and chair the Transition Committee. The company continues to focus on developing cancer and immune metabolism therapeutics through its Barer Institute and investments in clinical-stage companies.
Rafael Pharmaceuticals announced positive developments in its Phase 2 clinical trial for CPI-613® (devimistat) combined with gemcitabine and cisplatin in treating biliary tract cancer. The trial, now open at multiple prestigious cancer centers, continues to show a strong enrollment rate and maintains safety standards. This cancer type is rare, with less than 20,000 cases annually in the U.S. and a low survival rate. CPI-613® is designed to target cancer cell metabolism, enhancing chemotherapy efficacy while potentially reducing side effects.
Rafael Pharmaceuticals has announced the successful completion of the first cohort in the APOLLO 613 Phase 1/2 clinical trial for CPI-613® (devimistat), aimed at treating relapsed clear cell sarcoma, with no dose-limiting toxicity observed. Patient enrollment for the second cohort has commenced, reflecting a significant unmet need for effective rare cancer treatments. The trial expands to additional sites including Seattle Children’s and Atrium Health Wake Forest Baptist. Devimistat targets mitochondrial cancer metabolism and is designated as an orphan drug by the FDA.
Rafael Holdings, Inc. (NYSE: RFL) reported significant financial losses in its Q1 FY2022 results, with a net loss of approximately $129.4 million or $6.49 per share, largely due to impairments related to Rafael Pharmaceuticals. Revenues slightly decreased to $1.0 million from $1.1 million year-over-year. R&D expenses surged to $2.2 million, up from $0.5 million in the prior year, while SG&A expenses rose sharply to $12.9 million driven by stock-based compensation. The leadership transition is set for February 1, 2022, aiming to refine strategic focus.
Rafael Pharmaceuticals announced a significant publication detailing its Phase 2 clinical trial results of CPI-613 (devimistat) for refractory Burkitt lymphoma. A key highlight was a patient achieving near complete metabolic remission after four cycles, leading to complete remission after seven cycles, showcasing potential where few treatment options exist. The trial is ongoing, with recruitment at prestigious institutions like MD Anderson and Memorial Sloan Kettering. Rafael's pipeline includes further site openings planned for Q1 2022, aiming to enhance treatment options for rare cancers.
